Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$111.49 /

+5.21 (+4.90%)

07:28
06/18/20
06/18
07:28
06/18/20
07:28

BioMarin price target raised to $95 from $88 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the firm's price target on BioMarin to $95 from $88 and keeps a Perform rating on the shares. The analyst notes that incremental Phase 2 Roctavian data has been presented virtually at the World Federation of Hemophilia come essentially in-line. Respective three- and four-year experience with 4e13 and 6e13 vg/kg doses demonstrate maintenance of clinical benefit, while FVIII activity continues to decline, albeit at a more gradual rate, he highlights. Gershell continues to anticipate accelerated approval on/around the 8/21 PDUFA date, and believes the demonstration of meaningful clinical benefit out to at least four years will support robust pricing. Nonetheless, he keeps a tempered view on commercial uptake in light of physician commentary.

  • 21

    Aug

BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

06/17/20 RBC Capital
RBC Capital says buy BioMarin on the dip after presenting Roctavian data
06/17/20 Piper Sandler
Piper sees BioMarin having 'revolutionary long-term option' for Hemophilia A
06/10/20 BofA
BioMarin price target raised to $130 from $120 at BofA
06/05/20 Barclays
BioMarin price target raised to $125 from $105 at Barclays

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 01:45
07/15/20
07/15
01:45
07/15/20
01:45

Asian Market Update: The…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
The Bank of Japan maintained policy settings » 01:40
07/15/20
07/15
01:40
07/15/20
01:40

The Bank of Japan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Initiation
Extreme Networks initiated with a Buy at B. Riley FBR » 21:36
07/14/20
07/14
21:36
07/14/20
21:36
EXTR

Extreme Networks

$4.11 /

+0.215 (+5.52%)

B. Riley FBR initiated…

B. Riley FBR initiated coverage of Extreme Networks with a Buy rating and $7.50 price target.

ShowHide Related Items >><<
EXTR Extreme Networks
$4.11 /

+0.215 (+5.52%)

EXTR Extreme Networks
$4.11 /

+0.215 (+5.52%)

06/04/20 Lake Street
Extreme Networks price target raised to $5 from $4 at Lake Street
04/14/20 JPMorgan
Extreme Networks initiated with a Neutral at JPMorgan
04/09/20 Lake Street
Extreme Networks price target lowered to $4 from $7 at Lake Street
07/29/19 Lake Street
Extreme Networks initiated with a Buy at Lake Street
EXTR Extreme Networks
$4.11 /

+0.215 (+5.52%)

EXTR Extreme Networks
$4.11 /

+0.215 (+5.52%)

Hot Stocks
SPDR Gold Shares holdings rise to 1,206.89MT from 1,203.97MT » 20:56
07/14/20
07/14
20:56
07/14/20
20:56
GLD

SPDR Gold Shares

$170.15 /

+0.79 (+0.47%)

This is the second…

This is the second consecutive increase and the highest level of holdings since April of 2013.

ShowHide Related Items >><<
GLD SPDR Gold Shares
$170.15 /

+0.79 (+0.47%)

GLD SPDR Gold Shares
$170.15 /

+0.79 (+0.47%)

GLD SPDR Gold Shares
$170.15 /

+0.79 (+0.47%)

GLD SPDR Gold Shares
$170.15 /

+0.79 (+0.47%)

Initiation
Glencore initiated with a Buy at Goldman Sachs » 20:54
07/14/20
07/14
20:54
07/14/20
20:54
GLNCY

Glencore

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Jack O'Brien initiated coverage of Glencore with a Buy rating and 220 GBp price target. The stock has fallen about 26% year-to-date because of a decline in consensus for earnings, the company's exposure to thermal coal, and its "comparatively" high leverage, the analyst tells investors in a research note. O'Brien anticipates Glencore earnings growth to inflect however, stating that its current stock price does note reflect that potential.

ShowHide Related Items >><<
GLNCY Glencore
$0.00 /

+ (+0.00%)

GLNCY Glencore
$0.00 /

+ (+0.00%)

06/23/20 Morgan Stanley
Glencore price target lowered to 220 GBp from 230 GBp at Morgan Stanley
06/08/20 JPMorgan
Glencore price target raised to 180 GBp from 170 GBp at JPMorgan
05/11/20 JPMorgan
Glencore price target raised to ZAR 4,000 from ZAR 3,900 at JPMorgan
05/07/20 Credit Suisse
Glencore downgraded to Neutral from Outperform at Credit Suisse
GLNCY Glencore
$0.00 /

+ (+0.00%)

Initiation
ArcelorMittal initiated with a Buy at Goldman Sachs » 20:51
07/14/20
07/14
20:51
07/14/20
20:51
MT

ArcelorMittal

$11.80 /

+0.2 (+1.72%)

Goldman Sachs analyst…

Goldman Sachs analyst Jack O'Brien initiated coverage of ArcelorMittal with a Buy rating and EUR 14 price target. The analyst cites the company's position as the world's leading integrated steel and mining company while noting expectations of recovering global steel demand due to rebounding construction and automotive industries. O'Brien adds that the "downgrade cycle" for Arcellor Mittal is at an inflection point as consensus for FY20 EBITDA has fallen about 70% since its 2018 peak while also noting the company's "healthy" balance sheet.

ShowHide Related Items >><<
MT ArcelorMittal
$11.80 /

+0.2 (+1.72%)

MT ArcelorMittal
$11.80 /

+0.2 (+1.72%)

07/14/20 JPMorgan
ArcelorMittal price target raised to EUR 9 from EUR 8.50 at JPMorgan
07/09/20 Deutsche Bank
ArcelorMittal shares offer upside despite 'challenging' Q2, says Deutsche Bank
07/02/20 UBS
ArcelorMittal price target lowered to EUR 11 from EUR 12 at UBS
06/23/20 Morgan Stanley
ArcelorMittal price target lowered to EUR 13.30 at Morgan Stanley
  • 12
    May
MT ArcelorMittal
$11.80 /

+0.2 (+1.72%)

MT ArcelorMittal
$11.80 /

+0.2 (+1.72%)

MT ArcelorMittal
$11.80 /

+0.2 (+1.72%)

Initiation
Anglo American initiated with a Neutral at Goldman Sachs » 20:45
07/14/20
07/14
20:45
07/14/20
20:45
NGLOY

Anglo American

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Jack O'Brien initiated coverage of Anglo American with a Neutral rating and 1,900 GBp price target. The analyst has a favorable view on the company's "high-quality" exposure to copper and iron ore but a cautions stance on its platinum group metals, or PGM, and diamonds business. in PGM, O'Brien forecasts a decline in palladium and rhodium price from the second half of this year, reflecting weak auto demand and a recovering South American supply.

ShowHide Related Items >><<
NGLOY Anglo American
$0.00 /

+ (+0.00%)

NGLOY Anglo American
$0.00 /

+ (+0.00%)

07/08/20 Barclays
Anglo American price target raised to 2,550 GBp from 2,400 GBp at Barclays
07/02/20 Deutsche Bank
Anglo American price target lowered to 2,200 GBp at Deutsche Bank
06/25/20 UBS
Anglo American price target raised to 1,800 GBp from 1,650 GBp at UBS
06/23/20 Morgan Stanley
Anglo American price target lowered to 1,840 GBp at Morgan Stanley
Earnings
Notable companies reporting before tomorrow's open » 20:25
07/14/20
07/14
20:25
07/14/20
20:25
UNH

UnitedHealth

$308.58 /

+8.57 (+2.86%)

, GS

Goldman Sachs

$214.29 /

+5.36 (+2.57%)

, USB

U.S. Bancorp

$36.27 /

-0.57 (-1.55%)

, PGR

Progressive

$84.50 /

+4.16 (+5.18%)

, PNC

PNC Financial

$101.34 /

-1.31 (-1.28%)

, BK

BNY Mellon

$38.99 /

+0.13 (+0.33%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include UnitedHealth (UNH), consensus $5.18... Goldman Sachs (GS), consensus $3.78... U.S. Bancorp (USB), consensus 22c... Progressive (PGR), consensus $1.74... PNC Financial (PNC), consensus 51c... Bank of New York Mellon (BK), consensus 91c.

ShowHide Related Items >><<
USB U.S. Bancorp
$36.27 /

-0.57 (-1.55%)

UNH UnitedHealth
$308.58 /

+8.57 (+2.86%)

PNC PNC Financial
$101.34 /

-1.31 (-1.28%)

PGR Progressive
$84.50 /

+4.16 (+5.18%)

GS Goldman Sachs
$214.29 /

+5.36 (+2.57%)

BK BNY Mellon
$38.99 /

+0.13 (+0.33%)

UNH UnitedHealth
$308.58 /

+8.57 (+2.86%)

07/14/20 KeyBanc
UnitedHealth competition won't impact Livongo near term, says KeyBanc
07/07/20 Cantor Fitzgerald
UnitedHealth likely to reiterate 2020 outlook, says Cantor Fitzgerald
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
07/01/20 SVB Leerink
UnitedHealth reinstated with an Outperform at SVB Leerink
GS Goldman Sachs
$214.29 /

+5.36 (+2.57%)

07/08/20 Seaport Global
Goldman Sachs initiated with a Buy at Seaport Global
06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/05/20 Wells Fargo
Goldman Sachs price target raised to $255 from $230 at Wells Fargo
06/04/20
Fly Intel: Top five analyst downgrades
USB U.S. Bancorp
$36.27 /

-0.57 (-1.55%)

07/02/20 RBC Capital
U.S. Bancorp price target lowered to $42 from $48 at RBC Capital
06/11/20 DA Davidson
U.S. Bancorp initiated with a Buy at DA Davidson
06/05/20 Wells Fargo
Bank of America price target raised to $35 from $30 at Wells Fargo
06/04/20 Wells Fargo
U.S. Bancorp price target raised to $46 from $40 at Wells Fargo
PGR Progressive
$84.50 /

+4.16 (+5.18%)

06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Piper Sandler
Progressive downgraded to Neutral from Overweight at Piper Sandler
06/01/20 BofA
Progressive reinstated with a Buy at BofA
04/14/20
Fly Intel: Top five analyst upgrades
PNC PNC Financial
$101.34 /

-1.31 (-1.28%)

06/05/20 Wells Fargo
PNC Financial price target raised to $148 from $121 at Wells Fargo
05/18/20 Standpoint Research
PNC Financial initiated with an Accumulate at Standpoint Research
05/15/20 Cowen
Cowen 'would be surprised' if Goldman tried to buy any big commercial banks
BK BNY Mellon
$38.99 /

+0.13 (+0.33%)

07/08/20 Seaport Global
BNY Mellon initiated with a Buy at Seaport Global
07/08/20 Jefferies
BNY Mellon upgraded to Buy on positive EPS revisions at Jefferies
07/08/20 Jefferies
BNY Mellon upgraded to Buy from Hold at Jefferies
06/11/20 Deutsche Bank
BNY Mellon named short-term investment idea at Deutsche Bank
USB U.S. Bancorp
$36.27 /

-0.57 (-1.55%)

UNH UnitedHealth
$308.58 /

+8.57 (+2.86%)

PNC PNC Financial
$101.34 /

-1.31 (-1.28%)

PGR Progressive
$84.50 /

+4.16 (+5.18%)

GS Goldman Sachs
$214.29 /

+5.36 (+2.57%)

BK BNY Mellon
$38.99 /

+0.13 (+0.33%)

USB U.S. Bancorp
$36.27 /

-0.57 (-1.55%)

UNH UnitedHealth
$308.58 /

+8.57 (+2.86%)

PNC PNC Financial
$101.34 /

-1.31 (-1.28%)

PGR Progressive
$84.50 /

+4.16 (+5.18%)

GS Goldman Sachs
$214.29 /

+5.36 (+2.57%)

BK BNY Mellon
$38.99 /

+0.13 (+0.33%)

USB U.S. Bancorp
$36.27 /

-0.57 (-1.55%)

UNH UnitedHealth
$308.58 /

+8.57 (+2.86%)

PNC PNC Financial
$101.34 /

-1.31 (-1.28%)

PGR Progressive
$84.50 /

+4.16 (+5.18%)

GS Goldman Sachs
$214.29 /

+5.36 (+2.57%)

BK BNY Mellon
$38.99 /

+0.13 (+0.33%)

USB U.S. Bancorp
$36.27 /

-0.57 (-1.55%)

UNH UnitedHealth
$308.58 /

+8.57 (+2.86%)

PNC PNC Financial
$101.34 /

-1.31 (-1.28%)

PGR Progressive
$84.50 /

+4.16 (+5.18%)

GS Goldman Sachs
$214.29 /

+5.36 (+2.57%)

BK BNY Mellon
$38.99 /

+0.13 (+0.33%)

Syndicate
GoHealth 43.5M share IPO priced at $21.00 » 19:45
07/14/20
07/14
19:45
07/14/20
19:45
GOCO

GoHealth

$0.00 /

+ (+0.00%)

The deal size was…

The deal size was increased to 43.5M shares from 39.5M shares and priced above the $18.00-$20.00 target range. Goldman Sachs, BofA and Morgan Stanley are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 15
    Jul
GOCO GoHealth
$0.00 /

+ (+0.00%)

Hot Stocks
CoreLogic says Cannae, Senator have not revised proposal » 19:24
07/14/20
07/14
19:24
07/14/20
19:24
CLGX

CoreLogic

$67.01 /

+1.01 (+1.53%)

, CNNE

Cannae Holdings

$40.66 /

+1.085 (+2.74%)

CoreLogic (CLGX) issued…

CoreLogic (CLGX) issued the following statement following its meeting today with Senator Investment Group LP and Cannae Holdings Inc. (CNNE): "Members of the Company's Board of Directors and senior management met today with representatives of Cannae and Senator to learn more about their unsolicited proposal and discuss our value drivers and why our Board believes their current proposal significantly undervalues CoreLogic. We also discussed deal certainty, including financing and regulatory concerns. Despite the Company's recent guidance update for 2020 and disclosure of financial projections for 2021 and 2022, Senator and Cannae have not revised their proposal to deliver appropriate value to our shareholders. We are open to continuing our dialogue, but we are focused on delivering superior shareholder value by executing on our plan. We are experiencing strong momentum across our business and will update the market when we release our second quarter earnings." CoreLogic announced on July 7, 2020 that its Board of Directors had unanimously rejected the unsolicited proposal from Senator/Cannae that it received on June 26, 2020, to acquire all outstanding common shares of CoreLogic for $65.00 per share in cash. After a careful and thorough review, conducted in consultation with its independent financial and legal advisors, CoreLogic's Board of Directors unanimously concluded that the unsolicited proposal significantly undervalues the Company and is not in the best interests of its shareholders.

ShowHide Related Items >><<
CNNE Cannae Holdings
$40.66 /

+1.085 (+2.74%)

CLGX CoreLogic
$67.01 /

+1.01 (+1.53%)

CLGX CoreLogic
$67.01 /

+1.01 (+1.53%)

07/09/20 Barclays
CoreLogic downgraded to Equal Weight on limited upside at Barclays
07/09/20 Barclays
CoreLogic downgraded to Equal Weight from Overweight at Barclays
06/29/20 Zelman
Black Knight added as Buy to Top Idea Basket at Zelman
06/29/20 SunTrust
CoreLogic upgraded to Buy from Hold at SunTrust
CNNE Cannae Holdings
$40.66 /

+1.085 (+2.74%)

06/26/20 SunTrust
CoreLogic upgraded to Buy from Hold at SunTrust
05/14/20 Stephens
Cannae Holdings price target raised to $43 from $40 at Stephens
11/20/19 Stephens
Stephens says 'don't worry' about new CEO at Cannae Holdings
CLGX CoreLogic
$67.01 /

+1.01 (+1.53%)

  • 11
    Jun
  • 04
    Dec
CLGX CoreLogic
$67.01 /

+1.01 (+1.53%)

CNNE Cannae Holdings
$40.66 /

+1.085 (+2.74%)

CLGX CoreLogic
$67.01 /

+1.01 (+1.53%)

Hot Stocks
September-month U.S. equity index futures higher on COVID-19 vaccine news » 19:16
07/14/20
07/14
19:16
07/14/20
19:16
JBLU

JetBlue

$10.38 /

+0.2 (+1.96%)

, DAL

Delta Air Lines

$26.12 /

-0.71 (-2.65%)

, CCL

Carnival

$15.05 /

-0.225 (-1.47%)

, RCL

Royal Caribbean

$48.15 /

-1.37 (-2.77%)

, NCLH

Norwegian Cruise Line

$15.33 /

-0.28 (-1.79%)

, MRNA

Moderna

$75.04 /

+3.32 (+4.63%)

, DIA

Diamonds Fund ETF

$266.52 /

+5.48 (+2.10%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$318.93 /

+4.12 (+1.31%)

, UAL

United Airlines

$31.75 /

-0.01 (-0.03%)

, AAL

American Airlines

$11.57 /

-0.06 (-0.52%)

, PLAY

Dave & Buster's

$11.61 /

-0.18 (-1.53%)

, CAKE

Cheesecake Factory

$20.59 /

-0.42 (-2.00%)

, DIS

Disney

$118.70 /

+2.53 (+2.18%)

, SIX

Six Flags

$19.15 /

-0.33 (-1.69%)

In early electronic…

In early electronic trade, September-month U.S. equity futures are higher on positive COVID-19 vaccine developments after Moderna's (MRNA) formal press release disclosing The New England Journal of Medicine-published data, with all patients tested in the company's mRNA-1273 vaccine for COVID-19 producing antibodies. Nasdaq futures are up 0.7%, S&P500 e-mini's are up 0.9% and Dow Jones Industrial Average futures are up over 1%. Sectors driven down by travel restrictions such as Cruise Line operators, are seeing especially pronounced advances, with Carnival (CCL) up 7.1%, Norwegian Cruise Lines (NCLH) up 6.0%, and Royal Caribbean (RCL) up 7.8%. Airline stocks are also moving higher after-hours - Delta Air Lines (DAL) is up 4.9%, JetBlue Airways (JBLU) up 5.8%, United Airlines (UAL) is up 6.8%, and American Air Lines (AAL) is up 7.2%. In-store dining oriented restaurant names are also moving higher on the news with Dave & Busters (PLAY) up 12.3% and Cheesecake Factory (CAKE) up 7.8%. Theme parks-oriented stocks are higher as well, with Disney (DIS) up 2.3% and Six Flags (SIX) up 5.0% in the after-hours session.

ShowHide Related Items >><<
UAL United Airlines
$31.75 /

-0.01 (-0.03%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SIX Six Flags
$19.15 /

-0.33 (-1.69%)

RCL Royal Caribbean
$48.15 /

-1.37 (-2.77%)

PLAY Dave & Buster's
$11.61 /

-0.18 (-1.53%)

NCLH Norwegian Cruise Line
$15.33 /

-0.28 (-1.79%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

JBLU JetBlue
$10.38 /

+0.2 (+1.96%)

DIS Disney
$118.70 /

+2.53 (+2.18%)

DAL Delta Air Lines
$26.12 /

-0.71 (-2.65%)

CCL Carnival
$15.05 /

-0.225 (-1.47%)

CAKE Cheesecake Factory
$20.59 /

-0.42 (-2.00%)

AAL American Airlines
$11.57 /

-0.06 (-0.52%)

JBLU JetBlue
$10.38 /

+0.2 (+1.96%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/29/20 Goldman Sachs
JetBlue price target raised to $17 from $12 at Goldman Sachs
06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
JetBlue initiated with a Buy at Seaport Global
DAL Delta Air Lines
$26.12 /

-0.71 (-2.65%)

06/29/20 Goldman Sachs
Delta Air Lines price target raised to $38 from $33 at Goldman Sachs
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
06/10/20 JPMorgan
Delta Air Lines price target lowered to $41 from $45 at JPMorgan
CCL Carnival
$15.05 /

-0.225 (-1.47%)

07/14/20
Fly Intel: Top five analyst downgrades
07/14/20 SunTrust
Cruise Line operators downgraded at SunTrust on delayed starting dates
07/14/20 SunTrust
Carnival downgraded to Sell from Hold at SunTrust
07/14/20 Macquarie
Carnival downgraded to Neutral from Outperform at Macquarie
RCL Royal Caribbean
$48.15 /

-1.37 (-2.77%)

07/14/20 SunTrust
Royal Caribbean downgraded to Hold from Buy at SunTrust
07/14/20 Macquarie
Royal Caribbean downgraded to Neutral from Outperform at Macquarie
NCLH Norwegian Cruise Line
$15.33 /

-0.28 (-1.79%)

07/14/20 SunTrust
Norwegian Cruise Line downgraded to Hold from Buy at SunTrust
07/14/20 Macquarie
Norwegian Cruise Line downgraded to Neutral from Outperform at Macquarie
MRNA Moderna
$75.04 /

+3.32 (+4.63%)

07/14/20 Piper Sandler
Moderna COVID vaccine trial on track for July start, says Piper Sandler
07/13/20 Brookline
Moderna initiated with a Buy at Brookline
07/13/20 Jefferies
Jefferies starts Moderna with Buy rating, $90 price target
07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
DIA Diamonds Fund ETF
$266.52 /

+5.48 (+2.10%)

SPX S&P 500
$0.00 /

+ (+0.00%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

UAL United Airlines
$31.75 /

-0.01 (-0.03%)

06/29/20 Goldman Sachs
United Airlines price target raised to $61 from $40 at Goldman Sachs
06/17/20 Seaport Global
United Airlines initiated with a Buy at Seaport Global
AAL American Airlines
$11.57 /

-0.06 (-0.52%)

06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
PLAY Dave & Buster's
$11.61 /

-0.18 (-1.53%)

06/12/20
Fly Intel: Top five analyst upgrades
06/12/20 BMO Capital
Dave & Buster's price target raised to $15 from $13 at BMO Capital
06/12/20
Dave & Buster's upgraded to Buy at SunTrust on growing sales at reopened stores
06/12/20 SunTrust
Dave & Buster's upgraded to Buy from Hold at SunTrust
CAKE Cheesecake Factory
$20.59 /

-0.42 (-2.00%)

07/09/20 Credit Suisse
Cheesecake Factory initiated with a Neutral at Credit Suisse
07/01/20 Gordon Haskett
Cheesecake Factory downgraded to Hold as reopenings pause at Gordon Haskett
07/01/20 Gordon Haskett
Cheesecake Factory downgraded to Hold from Buy at Gordon Haskett
06/24/20
Fly Intel: Top five analyst downgrades
DIS Disney
$118.70 /

+2.53 (+2.18%)

07/13/20
Fly Intel: Top five analyst initiations
07/13/20 Goldman Sachs
Disney initiated with a Buy at Goldman Sachs
07/10/20 JPMorgan
JPMorgan has 'increasing conviction' in Disney returning to health
07/08/20 Guggenheim
Disney price target raised to $123 from $115 at Guggenheim
SIX Six Flags
$19.15 /

-0.33 (-1.69%)

07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Janney Montgomery Scott
Janney Montgomery Scott upgrades Six Flags to Buy in theme park preference shift
07/09/20 Janney Montgomery Scott
Six Flags upgraded to Buy from Neutral at Janney Montgomery Scott
06/15/20 B. Riley FBR
B. Riley FBR upgrades Six Flags ahead of China development plans
UAL United Airlines
$31.75 /

-0.01 (-0.03%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SIX Six Flags
$19.15 /

-0.33 (-1.69%)

RCL Royal Caribbean
$48.15 /

-1.37 (-2.77%)

PLAY Dave & Buster's
$11.61 /

-0.18 (-1.53%)

NCLH Norwegian Cruise Line
$15.33 /

-0.28 (-1.79%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

JBLU JetBlue
$10.38 /

+0.2 (+1.96%)

DIS Disney
$118.70 /

+2.53 (+2.18%)

DAL Delta Air Lines
$26.12 /

-0.71 (-2.65%)

CCL Carnival
$15.05 /

-0.225 (-1.47%)

CAKE Cheesecake Factory
$20.59 /

-0.42 (-2.00%)

AAL American Airlines
$11.57 /

-0.06 (-0.52%)

  • 23
    Jun
  • 19
    May
  • 06
    May
  • 04
    May
  • 22
    Apr
  • 02
    Apr
  • 12
    Feb
UAL United Airlines
$31.75 /

-0.01 (-0.03%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SIX Six Flags
$19.15 /

-0.33 (-1.69%)

RCL Royal Caribbean
$48.15 /

-1.37 (-2.77%)

PLAY Dave & Buster's
$11.61 /

-0.18 (-1.53%)

NCLH Norwegian Cruise Line
$15.33 /

-0.28 (-1.79%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

JBLU JetBlue
$10.38 /

+0.2 (+1.96%)

DIS Disney
$118.70 /

+2.53 (+2.18%)

DIA Diamonds Fund ETF
$266.52 /

+5.48 (+2.10%)

DAL Delta Air Lines
$26.12 /

-0.71 (-2.65%)

CCL Carnival
$15.05 /

-0.225 (-1.47%)

CAKE Cheesecake Factory
$20.59 /

-0.42 (-2.00%)

AAL American Airlines
$11.57 /

-0.06 (-0.52%)

UAL United Airlines
$31.75 /

-0.01 (-0.03%)

SIX Six Flags
$19.15 /

-0.33 (-1.69%)

RCL Royal Caribbean
$48.15 /

-1.37 (-2.77%)

PLAY Dave & Buster's
$11.61 /

-0.18 (-1.53%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

JBLU JetBlue
$10.38 /

+0.2 (+1.96%)

DIS Disney
$118.70 /

+2.53 (+2.18%)

DAL Delta Air Lines
$26.12 /

-0.71 (-2.65%)

CCL Carnival
$15.05 /

-0.225 (-1.47%)

CAKE Cheesecake Factory
$20.59 /

-0.42 (-2.00%)

AAL American Airlines
$11.57 /

-0.06 (-0.52%)

UAL United Airlines
$31.75 /

-0.01 (-0.03%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SIX Six Flags
$19.15 /

-0.33 (-1.69%)

RCL Royal Caribbean
$48.15 /

-1.37 (-2.77%)

PLAY Dave & Buster's
$11.61 /

-0.18 (-1.53%)

NCLH Norwegian Cruise Line
$15.33 /

-0.28 (-1.79%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

JBLU JetBlue
$10.38 /

+0.2 (+1.96%)

DIS Disney
$118.70 /

+2.53 (+2.18%)

DIA Diamonds Fund ETF
$266.52 /

+5.48 (+2.10%)

DAL Delta Air Lines
$26.12 /

-0.71 (-2.65%)

CCL Carnival
$15.05 /

-0.225 (-1.47%)

CAKE Cheesecake Factory
$20.59 /

-0.42 (-2.00%)

AAL American Airlines
$11.57 /

-0.06 (-0.52%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPX S&P 500
$0.00 /

+ (+0.00%)

DIA Diamonds Fund ETF
$266.52 /

+5.48 (+2.10%)

Recommendations
Investors should take 'fresh look' at Neuronetics after CEO hire, says Piper » 19:12
07/14/20
07/14
19:12
07/14/20
19:12
STIM

Neuronetics

$1.99 /

+0.08 (+4.19%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $6 price target on Neuronetics after it named Keith Sullivan to the position of CEO, effective immediately. O'Brien said he anticipates the announcement will be well-received by investors given Sullivan's success at ZELTIQ. The analyst added that he remains constructive on the company's ability to weather this period of disruption and further penetrate the multi-billion dollar depression market.

ShowHide Related Items >><<
STIM Neuronetics
$1.99 /

+0.08 (+4.19%)

STIM Neuronetics
$1.99 /

+0.08 (+4.19%)

05/05/20 William Blair
William Blair downgrades Neuronetics on restructuring uncertainty
05/05/20 William Blair
Neuronetics downgraded to Market Perform from Outperform at William Blair
05/05/20 Piper Sandler
Neuronetics' COVID-19 response measures the right decision, says Piper
04/09/20 Canaccord
Neuronetics price target lowered to $4 from $7 at Canaccord
STIM Neuronetics
$1.99 /

+0.08 (+4.19%)

On The Fly
Fly Intel: After-Hours Movers » 19:00
07/14/20
07/14
19:00
07/14/20
19:00
LCII

LCI Industries

$112.96 /

+3.12 (+2.84%)

, MRNA

Moderna

$75.04 /

+3.32 (+4.63%)

, LVGO

Livongo Health

$101.18 /

+3.81 (+3.91%)

, PVH

PVH Corp.

$46.52 /

+1.14 (+2.51%)

, VNOM

Viper Energy

$10.05 /

+0.48 (+5.02%)

, TALO

Talos Energy

$7.85 /

+0.28 (+3.70%)

, GSK

GlaxoSmithKline

$40.70 /

+0.635 (+1.58%)

, KRUS

Kura Sushi

$11.09 /

-1.34 (-10.78%)

, ZYXI

Zynex

$26.20 /

+0.115 (+0.44%)

, ADPT

Adaptive Biotechnologies

$43.18 /

-0.98 (-2.22%)

Open Full Text

ShowHide Related Items >><<
ZYXI Zynex
$26.20 /

+0.115 (+0.44%)

VNOM Viper Energy
$10.05 /

+0.48 (+5.02%)

TALO Talos Energy
$7.85 /

+0.28 (+3.70%)

PVH PVH Corp.
$46.52 /

+1.14 (+2.51%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

LCII LCI Industries
$112.96 /

+3.12 (+2.84%)

KRUS Kura Sushi
$11.09 /

-1.34 (-10.78%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

ADPT Adaptive Biotechnologies
$43.18 /

-0.98 (-2.22%)

LCII LCI Industries
$112.96 /

+3.12 (+2.84%)

07/06/20 Citi
LCI Industries initiated with a Neutral at Citi
05/07/20 Sidoti
LCI Industries downgraded to Neutral from Buy at Sidoti
04/17/20 Wolfe Research
LCI Industries initiated with an Outperform at Wolfe Research
03/17/20 Sidoti
LCI Industries upgraded to Buy from Neutral at Sidoti
MRNA Moderna
$75.04 /

+3.32 (+4.63%)

07/14/20 Piper Sandler
Moderna COVID vaccine trial on track for July start, says Piper Sandler
07/13/20 Brookline
Moderna initiated with a Buy at Brookline
07/13/20 Jefferies
Jefferies starts Moderna with Buy rating, $90 price target
07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

07/14/20 Credit Suisse
Livongo Health initiated with an Outperform at Credit Suisse
07/14/20 KeyBanc
UnitedHealth competition won't impact Livongo near term, says KeyBanc
07/14/20 Citi
Livongo Health initiated with a Buy at Citi
07/09/20 Canaccord
Livongo Health price target raised to $110 from $69 at Canaccord
PVH PVH Corp.
$46.52 /

+1.14 (+2.51%)

06/15/20 DA Davidson
PVH Corp. price target raised to $60 from $41 at DA Davidson
06/15/20 Barclays
PVH Corp. price target lowered to $51 from $67 at Barclays
06/15/20 RBC Capital
PVH Corp. price target raised to $48 from $30 at RBC Capital
06/12/20 Deutsche Bank
PVH Corp. price target lowered to $42 from $44 at Deutsche Bank
VNOM Viper Energy
$10.05 /

+0.48 (+5.02%)

06/22/20 Goldman Sachs
Diamondback Energy downgraded to Neutral from Buy at Goldman Sachs
06/12/20 KeyBanc
Viper Energy price target raised to $13 from $10 at KeyBanc
03/30/20 Citi
Viper Energy price target lowered to $12 from $35 at Citi
03/27/20 Imperial Capital
Viper Energy price target lowered to $10 from $30 at Imperial Capital
TALO Talos Energy
$7.85 /

+0.28 (+3.70%)

07/14/20 Stifel
Talos Energy initiated with a Buy at Stifel
06/25/20 MKM Partners
Talos Energy initiated with a Buy at MKM Partners
06/24/20 MKM Partners
Talos Energy initiated with a Buy at MKM Partners
06/04/20
Fly Intel: Top five analyst initiations
GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
KRUS Kura Sushi
$11.09 /

-1.34 (-10.78%)

07/10/20
Fly Intel: Top five analyst downgrades
07/10/20 Craig-Hallum
Kura Sushi downgraded to Hold from Buy at Craig-Hallum
06/16/20 Roth Capital
Kura Sushi initiated with a Buy at Roth Capital
04/27/20
Fly Intel: Top five analyst initiations
ZYXI Zynex
$26.20 /

+0.115 (+0.44%)

07/13/20 B. Riley FBR
Zynex downgraded to Neutral on valuation at B. Riley FBR
07/13/20 B. Riley FBR
Zynex downgraded to Neutral from Buy at B. Riley FBR
07/10/20 H.C. Wainwright
Zynex price target raised to $30 from $20 at H.C. Wainwright
06/16/20 Northland
Zynex downgraded to Market Perform from Outperform at Northland
ADPT Adaptive Biotechnologies
$43.18 /

-0.98 (-2.22%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
ZYXI Zynex
$26.20 /

+0.115 (+0.44%)

VNOM Viper Energy
$10.05 /

+0.48 (+5.02%)

TALO Talos Energy
$7.85 /

+0.28 (+3.70%)

PVH PVH Corp.
$46.52 /

+1.14 (+2.51%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

LCII LCI Industries
$112.96 /

+3.12 (+2.84%)

KRUS Kura Sushi
$11.09 /

-1.34 (-10.78%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

ADPT Adaptive Biotechnologies
$43.18 /

-0.98 (-2.22%)

  • 15
    Jul
  • 15
    Jul
  • 19
    May
  • 12
    Feb
  • 24
    Jan
  • 12
    Dec
  • 01
    Aug
  • 25
    Jul
MRNA Moderna
$75.04 /

+3.32 (+4.63%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

VNOM Viper Energy
$10.05 /

+0.48 (+5.02%)

TALO Talos Energy
$7.85 /

+0.28 (+3.70%)

PVH PVH Corp.
$46.52 /

+1.14 (+2.51%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

KRUS Kura Sushi
$11.09 /

-1.34 (-10.78%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

ADPT Adaptive Biotechnologies
$43.18 /

-0.98 (-2.22%)

VNOM Viper Energy
$10.05 /

+0.48 (+5.02%)

PVH PVH Corp.
$46.52 /

+1.14 (+2.51%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

Periodicals
POTUS signs Hong Kong sanctions legislation, WSJ reports » 18:59
07/14/20
07/14
18:59
07/14/20
18:59
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$318.93 /

+4.12 (+1.31%)

U.S. President Donald…

U.S. President Donald Trump has signed into law a bipartisan measure that requires sanctions on Chinese officials who crack down on the rights of Hong Kong residents to free speech and peaceful assembly, as well as lenders that do business with such officials, the Wall Street Journal's Lindsay Wise and Andrew Restuccia report. The president also said he had signed an executive order that he claims would end preferential U.S. treatment for Hong Kong, the authors say, noting that such preferential policies covered everything from trade to travel and extradition. "We've all watched what happened-not a good situation. Their freedoms have been taken away, their rights have been taken away," Trump said of the people of Hong Kong. Reference Link

ShowHide Related Items >><<
SPX S&P 500
$0.00 /

+ (+0.00%)

SPX S&P 500
$0.00 /

+ (+0.00%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Hot Stocks
Dolphin Entertainment regains compliance with Nasdaq listing rule » 18:47
07/14/20
07/14
18:47
07/14/20
18:47
DLPN

Dolphin Entertainment

$1.09 /

-0.34 (-23.78%)

On July 14, 2020, Dolphin…

On July 14, 2020, Dolphin Entertainment, Inc. received a letter from the Nasdaq Stock Market notifying them that it had regained compliance under Nasdaq Listing Rule 5250(c)(1). On July 9, 2020, the company had received a letter from Nasdaq notifying them that it had violated Rule 5250(c)(1) because the Company had not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2020 with the SEC. On July 13, 2020, the company filed the Quarterly Report with the SEC and subsequently received a close-out letter from Nasdaq on July 14, 2020, which alerted the company that it had regained compliance under Rule 5250(c)(1).

ShowHide Related Items >><<
DLPN Dolphin Entertainment
$1.09 /

-0.34 (-23.78%)

DLPN Dolphin Entertainment
$1.09 /

-0.34 (-23.78%)

01/30/20 National Securities
Dolphin Entertainment initiated with a Buy at National Securities
DLPN Dolphin Entertainment
$1.09 /

-0.34 (-23.78%)

  • 17
    Oct
Hot Stocks
Paychex CEO: We ended the year pretty strong » 18:43
07/14/20
07/14
18:43
07/14/20
18:43
PAYX

Paychex

$71.95 /

+0.34 (+0.47%)

In an interview on…

In an interview on CNBC's Mad Money, Marty Mucci said clients are sticking with the company due to its great service. Paychex continues to generate great operating cash flow and is well positioned to continue paying a dividend, he said. Florida and the South are leading with job creation, Mucci noted. New business starts are now up year to date from last year. Half the companies that suspended processing are back, he said.

ShowHide Related Items >><<
PAYX Paychex
$71.95 /

+0.34 (+0.47%)

PAYX Paychex
$71.95 /

+0.34 (+0.47%)

07/14/20 Goldman Sachs
Paychex initiated with a Sell at Goldman Sachs
07/08/20 BMO Capital
Paychex price target raised to $74 from $70 at BMO Capital
07/08/20 Citi
Paychex price target raised to $75 from $65 at Citi
07/07/20 Jefferies
Paychex price target raised to $75 from $68 at Jefferies
PAYX Paychex
$71.95 /

+0.34 (+0.47%)

PAYX Paychex
$71.95 /

+0.34 (+0.47%)

Hot Stocks
Moderna extends gains after formal NEJM press release on mRNA-1273 COVID vaccine » 18:29
07/14/20
07/14
18:29
07/14/20
18:29
MRNA

Moderna

$75.04 /

+3.32 (+4.63%)

Shares of Moderna are…

Shares of Moderna are soaring after-hours following the company's formal press release disclosing the publication of its updated interim results of Phase 1 study of mRNA-1273 vaccine against COVID-19. The study, led by the National Institute of Allergy and Infectious Diseases, has updated results through Day 57 and re-affirmed the positive interim data in the initial interim update published on May 18th, showing that "mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2". The report, published in The New England Journal of Medicine, says that mRNA-1273 was generally safe and well-tolerated, with no serious adverse events reported through Day 57, Moderna said in a statement. As the company indicated in May, all participants ages 18-55 across the three dose levels tested had seroconverted by day 15 after a single dose. In today's update, Moderna states that after two vaccinations, at Day 57, geometric mean titers exceeded those seen in convalescent sera obtained from 38 individuals with confirmed COVID-19 diagnosis. Of these 38 individuals in the convalescent sera group, 15% were classified as having severe symptoms, 22% had moderate symptoms and 63% had mild symptoms. Commenting on the results, Moderna Chief Medical Officer Tal Zaks stated: "These Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 microgram in a prime and boost regimen as the optimal dose for the Phase 3 study". Moderna CEO Stephane Bancel also suggested that "Moderna team continues to focus on starting our Phase 3 study this month and, if successful, filing a BLA". At the time of writing, shares of Moderna are up 13.7% afterhours, or $9.96 at $85.00 per share, extending today's regular session gains of 4.5% that followed a STAT publication previewing today's NEJM report and the expectation of a Phase 3 vaccine trial starting on July 27th.

ShowHide Related Items >><<
MRNA Moderna
$75.04 /

+3.32 (+4.63%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

07/14/20 Piper Sandler
Moderna COVID vaccine trial on track for July start, says Piper Sandler
07/13/20 Brookline
Moderna initiated with a Buy at Brookline
07/13/20 Jefferies
Jefferies starts Moderna with Buy rating, $90 price target
07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
MRNA Moderna
$75.04 /

+3.32 (+4.63%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$75.04 /

+3.32 (+4.63%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

MRNA Moderna
$75.04 /

+3.32 (+4.63%)

Hot Stocks
Livongo Health Founder: We work hand in hand with Teladoc » 18:22
07/14/20
07/14
18:22
07/14/20
18:22
LVGO

Livongo Health

$101.18 /

+3.81 (+3.91%)

, TDOC

Teladoc

$208.96 /

-9.53 (-4.36%)

In an interview on…

In an interview on CNBC's Mad Money, Glen Tullman said he expects many more companies to move to Livongo in the near future. Employers are doubling down on Livongo to keep employees productive and healthy, according to Tullman. Telehealth is one-on-one, but Livongo takes it to the next level, he noted.

ShowHide Related Items >><<
TDOC Teladoc
$208.96 /

-9.53 (-4.36%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

07/14/20 Credit Suisse
Livongo Health initiated with an Outperform at Credit Suisse
07/14/20 KeyBanc
UnitedHealth competition won't impact Livongo near term, says KeyBanc
07/14/20 Citi
Livongo Health initiated with a Buy at Citi
07/09/20 Canaccord
Livongo Health price target raised to $110 from $69 at Canaccord
TDOC Teladoc
$208.96 /

-9.53 (-4.36%)

07/14/20 Citi
Teladoc initiated with a Buy at Citi
07/13/20 Argus
Teladoc initiated with a Buy at Argus
07/13/20 Argus
Teladoc initiated with a Buy at Argus
07/06/20 Stephens
Teladoc initiated with an Overweight at Stephens
TDOC Teladoc
$208.96 /

-9.53 (-4.36%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

  • 12
    Dec
  • 25
    Jul
TDOC Teladoc
$208.96 /

-9.53 (-4.36%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

TDOC Teladoc
$208.96 /

-9.53 (-4.36%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

TDOC Teladoc
$208.96 /

-9.53 (-4.36%)

LVGO Livongo Health
$101.18 /

+3.81 (+3.91%)

Periodicals
BHP faces first step in $6.3B lawsuit over Brazil dam disaster, Reuters says » 18:20
07/14/20
07/14
18:20
07/14/20
18:20
BHP

BHP Group

$52.36 /

+1.59 (+3.13%)

Over 200,000 Brazilian…

Over 200,000 Brazilian people and groups next week will initiate a $6.3B lawsuit against BHP in the U.K. over a 2015 dam failure that led to the South American nation's worst environmental disaster, Reuters' Kirstin Ridley reports. The group case is being pushed through on behalf of Brazilian individuals, businesses, churches, organisations, municipalities and indigenous people and will open in Manchester next week, Ridley says. An initial eight-day hearing will determine whether the claim can be heard in the U.K., although the judge is anticipated to reserve judgment until later in 2020, Ridley says, noting that, if successful, additional trials are expected to determine liability and quantify damages. Reference Link

ShowHide Related Items >><<
BHP BHP Group
$52.36 /

+1.59 (+3.13%)

BHP BHP Group
$52.36 /

+1.59 (+3.13%)

07/07/20 Goldman Sachs
Goldman Sachs downgrades Rio Tinto on relative value, prefers BHP
07/06/20
Fly Intel: Top five analyst downgrades
07/06/20 Credit Suisse
BHP Group downgraded to Neutral from Outperform at Credit Suisse
07/06/20 Credit Suisse
BHP Group downgraded to Neutral from Outperform at Credit Suisse
BHP BHP Group
$52.36 /

+1.59 (+3.13%)

BHP BHP Group
$52.36 /

+1.59 (+3.13%)

General news
Treasury Market Summary » 18:15
07/14/20
07/14
18:15
07/14/20
18:15

Treasury Market Summary:…

Treasury Market Summary: Wall Street bounced back robustly from Monday's wobble and following a tentative start to the day, with the Dow outperforming. The index jumped 2.1%, followed by a 1.3% gain in the S&amp;P 500 and a 0.9% rise in the NASDAQ. Stocks continued to gyrate between a dip-buying mentality, positive news on vaccines and therapeutics, and expectations for more stimulus, against escalating concerns that the reversal of reopenings will delay/harm the recovery. Also, earnings season got underway and added to the general uncertainties given expectations for massive weakness in Q2, but with ample scope that results could overshoot a very low bar. Much will also depend on guidance, though that's very shaky with about 30% of companies declining to provide outlooks and hence leaving a big information void. Treasuries were steady through the day, with yields richening slightly despite the rally in risk and the firmer than expected CPI report. CPI climbed 0.6% in June, with the core rate 0.2% firmer. But the core rate was steady at 1.2% y/y, far from the 2% y/y target. Dovish comments from Fed Governor Brainard helped underpin Wall Street but had little effect on Treasuries. View the summary.

Periodicals
Belgium fines Google EUR600K over privacy rule violation, Reuters says » 18:09
07/14/20
07/14
18:09
07/14/20
18:09
GOOG

Alphabet

$1,520.25 /

+8.6 (+0.57%)

, GOOGL

Alphabet Class A

$1,522.11 /

+11.3 (+0.75%)

Belgium's data…

Belgium's data protection authority has fined Google EUR600,000 for not complying with European rules over an individual's "right to be forgotten" online, Reuters' Kate Abnett reports. The penalty is the largest ever imposed by the authority, known as the APD, and more than 10 times bigger than the APD's prior record penalty, the author notes. The authority said that the U.S. search giant failed to remove links from its search results to articles which the APD said were "obsolete" and damaging to the reputation of a person with a public profile in the European country, Abnett says. Reference Link

ShowHide Related Items >><<
GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

07/13/20 Mizuho
Alphabet price target raised to $1,650 from $1,560 at Mizuho
07/13/20 Barclays
Alphabet price target raised to $1,600 from $1,400 at Barclays
07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
GOOGL Alphabet Class A
$1,522.11 /

+11.3 (+0.75%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

GOOGL Alphabet Class A
$1,522.11 /

+11.3 (+0.75%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

GOOGL Alphabet Class A
$1,522.11 /

+11.3 (+0.75%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

Periodicals
Wells Fargo CFO doesn't see dividend falling to zero, Bloomberg says » 18:04
07/14/20
07/14
18:04
07/14/20
18:04
WFC

Wells Fargo

$24.25 /

-1.18 (-4.64%)

Wells Fargo CFO John…

Wells Fargo CFO John Shrewsberry doesn't expect the dividend to go to zero, following the bank's slashing of the dividend earlier as part of its quarterly earnings report, Shrewsberry told Bloomberg TV. Reference Link

ShowHide Related Items >><<
WFC Wells Fargo
$24.25 /

-1.18 (-4.64%)

WFC Wells Fargo
$24.25 /

-1.18 (-4.64%)

07/10/20 Baird
Wells Fargo upgraded to Outperform from Neutral at Baird
07/09/20 Wolfe Research
Wells Fargo upgraded to Peer Perform from Underperform at Wolfe Research
07/08/20 JPMorgan
Wells Fargo price target lowered to $29.50 from $32 at JPMorgan
07/08/20 Seaport Global
Wells Fargo initiated with a Neutral at Seaport Global
WFC Wells Fargo
$24.25 /

-1.18 (-4.64%)

WFC Wells Fargo
$24.25 /

-1.18 (-4.64%)

WFC Wells Fargo
$24.25 /

-1.18 (-4.64%)

WFC Wells Fargo
$24.25 /

-1.18 (-4.64%)

Hot Stocks
GlaxoSmithKline gets favorable FDA advisory cmte vote on belantamab mafodotin » 17:48
07/14/20
07/14
17:48
07/14/20
17:48
GSK

GlaxoSmithKline

$40.70 /

+0.635 (+1.58%)

GlaxoSmithKline announced…

GlaxoSmithKline announced the FDA Oncologic Drugs Advisory Committee, or ODAC, voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. Two committee members could not participate in the final vote. The recommendation was based on data from the DREAMM clinical trial programme, including the pivotal DREAMM-2 study which enrolled heavily pre-treated patients who had actively progressing multiple myeloma that had worsened despite current standard of care.i The six-month primary results from the study were published in The Lancet Oncology in December 2019 and serve as the basis for the Biologics License Application.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

GSK GlaxoSmithKline
$40.70 /

+0.635 (+1.58%)

Downgrade
GW Pharmaceuticals downgraded to Hold from Buy at Stifel » 17:37
07/14/20
07/14
17:37
07/14/20
17:37
GWPH

GW Pharmaceuticals

$139.38 /

+7.11 (+5.38%)

Stifel analyst Paul…

Stifel analyst Paul Matteis downgraded GW Pharmaceuticals to Hold from Buy with a price target of $140, down from $150. While the analyst sees the company's Q2 beating consensus, he believes "conservative physician expectations for Epidiolex use in 'off-label' refractory epilepsy" deviates significantly from the bull case and leads to a change in his rating and price target.

ShowHide Related Items >><<
GWPH GW Pharmaceuticals
$139.38 /

+7.11 (+5.38%)

GWPH GW Pharmaceuticals
$139.38 /

+7.11 (+5.38%)

06/30/20 Evercore ISI
GW Pharmaceuticals price target raised to $275 from $250 at Evercore ISI
06/01/20 Oppenheimer
GW Pharmaceuticals assumed with an Outperform at Oppenheimer
05/14/20 Cantor Fitzgerald
GW Pharmaceuticals price target raised to $154 from $120 at Cantor Fitzgerald
04/08/20 Northland
GW Pharmaceuticals initiated with an Outperform at Northland
GWPH GW Pharmaceuticals
$139.38 /

+7.11 (+5.38%)

GWPH GW Pharmaceuticals
$139.38 /

+7.11 (+5.38%)

Periodicals
Ruth Bader Ginsburg hospitalized for possible infection, CNBC reports » 17:29
07/14/20
07/14
17:29
07/14/20
17:29
SPY

SPDR S&P 500 ETF Trust

$318.93 /

+4.12 (+1.31%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

, QQQ

Invesco QQQ Trust

$260.39 /

+1.86 (+0.72%)

Supreme Court Justice…

Supreme Court Justice Ruth Bader Ginsburg hospitalized for possible infection, CNBC reports. Reference Link

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPX S&P 500
$0.00 /

+ (+0.00%)

QQQ Invesco QQQ Trust
$260.39 /

+1.86 (+0.72%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

QQQ Invesco QQQ Trust
$260.39 /

+1.86 (+0.72%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPX S&P 500
$0.00 /

+ (+0.00%)

QQQ Invesco QQQ Trust
$260.39 /

+1.86 (+0.72%)

SPY SPDR S&P 500 ETF Trust
$318.93 /

+4.12 (+1.31%)

SPX S&P 500
$0.00 /

+ (+0.00%)

QQQ Invesco QQQ Trust
$260.39 /

+1.86 (+0.72%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.